
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3511492/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Protein Engineering and HDX Identify Structural Regions of G-CSF Critical to Its Stability and Aggregation. Molecular Pharmaceutics, 2022, 19, 616-629.	4.6	4
2	WHO informal consultation on revision of guidelines on evaluation of similar biotherapeutic products, virtual meeting, 30 June $\hat{a} \in 2$ July 2021. Biologicals, 2022, 76, 1-9.	1.4	2
3	2021 White Paper on Recent Issues in Bioanalysis: ISR for Biomarkers, Liquid Biopsies, Spectral Cytometry, Inhalation/Oral & Multispecific Biotherapeutics, Accuracy/LLOQ for Flow Cytometry ( <u>Part 2</u> – Recommendations on Biomarkers/CDx Assays Development & Validation,) Tj ETQq1 1 0	.784314	rgBIQOverloc
4	2021 White Paper on Recent Issues in Bioanalysis: Mass Spec of Proteins, Extracellular Vesicles, CRISPR, Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Rare Matrices; Regulatory InputsÂ( <u>Part 1A</u> – Recommendations on Endogenous Compounds, Small Molecules,) Tj ETC	2q0 0 0 rş 1.5	gBT_/Overlock 14
5	2021 White Paper on Recent Issues in Bioanalysis: TAb/NAb, Viral Vector CDx, Shedding Assays; CRISPR/Cas9 & CAR-T Immunogenicity; PCR & Vaccine Assay Performance; ADA Assay Comparability & Cut Point AppropriatenessÂ( <u>Part 3</u> – Recommendations on Gene Therapy,) Tj ETG	)q <b>1</b> .fl 0.7	84 <b>3</b> 24 rgBT
6	Regulatory challenges with biosimilars: an update from 20 countries. Annals of the New York Academy of Sciences, 2021, 1491, 42-59.	3.8	20
7	Maintaining â€~standards' for biosimilar monoclonal antibodies. Nature Biotechnology, 2021, 39, 276-280.	17.5	12
8	The First WHO International Standard for Adalimumab: Dual Role in Bioactivity and Therapeutic Drug Monitoring. Frontiers in Immunology, 2021, 12, 636420.	4.8	7
9	Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19. Biomedicine and Pharmacotherapy, 2021, 140, 111785.	5.6	14
10	The First WHO International Standard for Harmonizing the Biological Activity of Bevacizumab. Biomolecules, 2021, 11, 1610.	4.0	2
11	WHO International Standards and Reference Preparations for Cytokines and Growth Factors. Journal of Leukocyte Biology, 2020, 107, 159-160.	3.3	0
12	Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs. AAPS Journal, 2020, 22, 7.	4.4	17
13	WHO implementation workshop on guidelines on procedures and data requirements for changes to approved biotherapeutic products, Seoul, Republic of Korea, 25–26 June 2019. Biologicals, 2020, 65, 50-59.	1.4	1
14	The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019. Biologicals, 2020, 65, 1-9.	1.4	34
15	Harmonization and standardization of immunogenicity assessment of biotherapeutic products. Bioanalysis, 2019, 11, 1593-1604.	1.5	8
16	Bioanalytical strategies in determining immunogenicity. Bioanalysis, 2019, 11, 1535-1537.	1.5	0
17	The impact of thioredoxin reduction of allosteric disulfide bonds on the therapeutic potential of monoclonal antibodies. Journal of Biological Chemistry, 2019, 294, 19616-19634.	3.4	10
18	The first World Health Organization International Standard for infliximab products: A step towards maintaining harmonized biological activity. MAbs, 2019, 11, 13-25.	5.2	16

#	Article	IF	CITATIONS
19	Endothelial cell functions impaired by interferon in vitro: Insights into the molecular mechanism of thrombotic microangiopathy associated with interferon therapy. Thrombosis Research, 2018, 163, 105-116.	1.7	41
20	WHO informal consultation on development of guidelines on procedures and data requirements for changes to approved biotherapeutic products, Seoul, Republic of Korea, 27–28 April 2017. Biologicals, 2018, 52, 83-91.	1.4	2
21	2018 White Paper on Recent Issues in Bioanalysis: focus on immunogenicity assays by hybrid LBA/LCMS and regulatory feedback (Part 2 – PK, PD & ADA assays by hybrid LBA/LCMS & regulatory) Tj ETQq1	1 017884314	4 r <b>gB</b> T /Overle
22	2018 White Paper on Recent Issues in Bioanalysis: focus on flow cytometry, gene therapy, cut points and key clarifications on BAV (Part 3 – LBA/cell-based assays: immunogenicity, biomarkers and PK) Tj ETQqO 0	0 ng₿T /O∖	verkløick 10 Tf :
23	Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab. Cytokine, 2017, 96, 16-23.	3.2	24
24	Surrogate CD16-expressing effector cell lines for determining the bioactivity of therapeutic monoclonal antibodies. Journal of Pharmaceutical and Biomedical Analysis, 2017, 143, 188-198.	2.8	6
25	Establishment of the first WHO International Standard for etanercept, a TNF receptor II Fc fusion protein: Report of an international collaborative study. Journal of Immunological Methods, 2017, 447, 14-22.	1.4	11
26	Influence of <i>Escherichia coli</i> chaperone DnaK on protein immunogenicity. Immunology, 2017, 150, 343-355.	4.4	18
27	IL-27 Promotes Proliferation of Human Leukemic Cell Lines Through the MAPK/ERK Signaling Pathway and Suppresses Sensitivity to Chemotherapeutic Drugs. Journal of Interferon and Cytokine Research, 2016, 36, 302-316.	1.2	25
28	Editor's Highlight: Subvisible Aggregates of Immunogenic Proteins Promote a Th1-Type Response. Toxicological Sciences, 2016, 153, 258-270.	3.1	33
29	Establishment of the first WHO Erythropoietin antibody reference panel: Report of an international collaborative study. Journal of Immunological Methods, 2016, 435, 32-42.	1.4	9
30	Quality and Batch-to-Batch Consistency of Original and Biosimilar Epoetin Products. Journal of Pharmaceutical Sciences, 2016, 105, 542-550.	3.3	18
31	Establishment of the first international standard for PEGylated granulocyte colony stimulating factor (PEG-G-CSF): Report of an international collaborative study. Journal of Immunological Methods, 2015, 416, 17-28.	1.4	12
32	Immunogenicity assessment of biotherapeutic products: An overview of assays and their utility. Biologicals, 2015, 43, 298-306.	1.4	114
33	Access to safe and effective biopharmaceuticals. GaBI Journal, 2015, 4, 108-109.	0.3	1
34	Standardization of Human IL-29 (IFN-λ1): Establishment of a World Health Organization International Reference Reagent for IL-29 (IFN-λ1). Journal of Interferon and Cytokine Research, 2014, 34, 876-884.	1.2	5
35	Detection of anti-cytokine antibodies and their clinical relevance. Expert Review of Clinical Immunology, 2014, 10, 1029-1047.	3.0	17
36	Biosimilar monoclonal antibodies approved for use in the EU. GaBI Journal, 2014, 3, 9-10.	0.3	2

#	Article	IF	CITATIONS
37	Use of a Standardized MxA Protein Measurement-Based Assay for Validation of Assays for the Assessment of Neutralizing Antibodies Against Interferon-β. Journal of Interferon and Cytokine Research, 2013, 33, 660-671.	1.2	17
38	Severity of the <scp>TGN</scp> 1412 trial disaster cytokine storm correlated with <scp>IL</scp> â€2 release. British Journal of Clinical Pharmacology, 2013, 76, 299-315.	2.4	56
39	The 2nd International standard for Interleukin-2 (IL-2) Report of a collaborative study. Journal of Immunological Methods, 2013, 397, 1-7.	1.4	3
40	Immunoglobulin G1 and immunoglobulin G4 antibodies in multiple sclerosis patients treated with IFNβ interact with the endogenous cytokine and activate complement. Clinical Immunology, 2013, 148, 177-185.	3.2	17
41	European perspective on biosimilars. Bioanalysis, 2013, 5, 521-524.	1.5	6
42	Development and characterization of a non-cell-based assay to assess the presence of neutralizing antibodies to interferon-beta in clinical samples. Journal of Immunological Methods, 2013, 395, 37-44.	1.4	15
43	Detection of neutralizing antibodies to erythropoietin by inhibition of rHuEPO-stimulated EGR1 gene expression in the UT-7/EPO cell line. Journal of Immunological Methods, 2013, 387, 191-198.	1.4	3
44	Biosimilars: what clinicians should know. Blood, 2012, 120, 5111-5117.	1.4	314
45	The 1st International standard for transforming growth factor-β3 (TGF-β3). Journal of Immunological Methods, 2012, 380, 1-9.	1.4	1
46	Freeze drying formulation using microscale and design of experiment approaches: a case study using granulocyte colony-stimulating factor. Biotechnology Letters, 2012, 34, 641-648.	2.2	14
47	An Assessment of Biological Potency and Molecular Characteristics of Different Innovator and Noninnovator Interferon-Beta Products. Journal of Interferon and Cytokine Research, 2011, 31, 383-392.	1.2	26
48	Endothelial cells co-stimulate peripheral blood mononuclear cell responses to monoclonal antibody TGN1412 in culture. Cytokine, 2011, 55, 141-151.	3.2	23
49	Biosimilars—why terminology matters. Nature Biotechnology, 2011, 29, 690-693.	17.5	174
50	The 2nd International Standard for human granulocyte colony stimulating factor. Journal of Immunological Methods, 2011, 367, 63-69.	1.4	6
51	Comparison of novel methods for predicting the risk of pro-inflammatory clinical infusion reactions during monoclonal antibody therapy. Journal of Immunological Methods, 2011, 371, 134-142.	1.4	27
52	Intended use of Reference Products & WHO International Standards/Reference Reagents in the development of Similar Biological Products (Biosimilars). Biologicals, 2011, 39, 262-265.	1.4	17
53	WHO/KFDA joint workshop on implementing WHO guidelines on evaluating similar biotherapeutic products, Seoul, Republic of Korea 24–26 August, 2010. Biologicals, 2011, 39, 349-357.	1.4	11
54	Evaluation of similar biotherapeutic products: Scientific and regulatory challenges. Biologicals, 2011, 39, 249.	1.4	1

#	Article	IF	CITATIONS
55	Treatment of colitis with a commensal gut bacterium engineered to secrete human tgf-β1 under the control of dietary xylan. Inflammatory Bowel Diseases, 2011, 17, 1925-1935.	1.9	83
56	Are neutralizing anti–CM-CSF autoantibodies present in all healthy persons?. Blood, 2010, 115, 433-434.	1.4	11
57	WHO international cytokine standards and reference preparations. Journal of Leukocyte Biology, 2010, 88, 425-426.	3.3	1
58	Unwanted immunogenicity: lessons learned and future challenges. Bioanalysis, 2010, 2, 1073-1084.	1.5	27
59	Detection of neutralizing interleukin-17 antibodies in autoimmune polyendocrinopathy syndrome-1 (APS-1) patients using a novel non-cell based electrochemiluminescence assay. Cytokine, 2010, 50, 129-137.	3.2	14
60	World Health Organization International Cytokine Standards and Reference Preparations. Journal of Interferon and Cytokine Research, 2010, 30, 639-641.	1.2	1
61	A novel bioassay for B-cell activating factor (BAFF) based on expression of a BAFF-receptor ectodomain-tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-2 endodomain fusion receptor in human rhabdomyosarcoma cells. Journal of Immunological Methods, 2008, 337, 63-70.	1.4	6
62	Haematopoietic growth factors and their therapeutic use. Thrombosis and Haemostasis, 2008, 99, 863-873.	3.4	40
63	Assessment of Unwanted Immunogenicity. , 2008, , 57-73.		4
64	Haematopoietic growth factors and their therapeutic use. Thrombosis and Haemostasis, 2008, 99, 863-73.	3.4	15
65	"Cytokine Storm―in the Phase I Trial of Monoclonal Antibody TGN1412: Better Understanding the Causes to Improve PreClinical Testing of Immunotherapeutics. Journal of Immunology, 2007, 179, 3325-3331.	0.8	311
66	Unwanted Immunogenicity: Implications for Follow-on Biologicals. Drug Information Journal, 2007, 41, 1-9.	0.5	10
67	Continuous delivery of human type I interferons ( $\hat{I} \pm / \hat{I}^2$ ) has significant activity against acute myeloid leukemia cells in vitro and in a xenograft model. Blood, 2007, 109, 1244-1247.	1.4	27
68	Strategies and Assays for the Assessment of Unwanted Immunogenicity. Journal of Immunotoxicology, 2006, 3, 115-121.	1.7	28
69	Biological activity of interleukins-28 and -29: Comparison with type I interferons. Cytokine, 2005, 31, 109-118.	3.2	202
70	Problems in early diagnosis of bladder cancer in a spinal cord injury patient: Report of a case of simultaneous production of granulocyte colony stimulating factor and parathyroid hormone-related protein by squamous cell carcinoma of urinary bladder. BMC Urology, 2002, 2, 8.	1.4	27
71	Cytokine levels as performance indicators for white blood cell reduction of platelet concentrates. Vox Sanguinis, 2002, 83, 125-136.	1.5	32
72	Chemokine/Chemokine Receptor Nomenclature. Journal of Interferon and Cytokine Research, 2002, 22, 1067-1068.	1.2	273

#	Article	IF	CITATIONS
73	Autologous plasma activates Akt/protein kinase B and enhances basal survival and resistance to DNA damage-induced apoptosis in B-chronic lymphocytic leukaemia cells. British Journal of Haematology, 2001, 114, 608-615.	2.5	30
74	Cytokines in WBC-reduced apheresis PCs during storage: a comparison of two WBC-reduction methods. Transfusion, 2000, 40, 1118-1126.	1.6	46
75	Sustained Expression of CD154 (CD40L) and Proinflammatory Cytokine Production by Alloantigen-Stimulated Umbilical Cord Blood T Cells. Journal of Immunology, 2000, 164, 6206-6212.	0.8	41
76	Are cytokines in platelet concentrates responsible for febrile transfusion reactions?. Transfusion Science, 1997, 18, 367-371.	0.6	5
77	Cytokine Contamination of Biological Products. Biologicals, 1997, 25, 307-318.	1.4	Ο
78	IL-4 and TNF-α-MEDIATED PROLIFERATION OF THE HUMAN MEGAKARYOCYTIC LINE M-O7E IS REGULATED BY INDUCED AUTOCRINE PRODUCTION OF GM-CSF. Cytokine, 1996, 8, 900-909.	3.2	7
79	Neutralising antibodies to granulocyte-macrophage colony stimulating factor (GM-CSF) in carcinoma patients following GM-CSF combination therapy. Medical Oncology, 1996, 13, 161-166.	2.5	15
80	Transforming growth factor-β1 blocks interleukin 4 induced cell proliferation by inhibiting a protein tyrosine phosphatase essential for signal transduction. Cytokine, 1994, 6, 389-398.	3.2	9
81	A novel, sensitive bioassay for transforming growth factor β. Journal of Immunological Methods, 1993, 164, 61-67.	1.4	32
82	Mechanisms of inhibition of T cell IL-2 secretion by factor VIII concentrates. British Journal of Haematology, 1992, 82, 575-583.	2.5	24
83	Development of immunoassays for human interleukin 3 and interleukin 4, some of which discriminate between different recombinant DNA-derived molecules. Cytokine, 1991, 3, 562-567.	3.2	21
84	Reconstitution of interleukin 2 with albumin for infusion. Lancet, The, 1990, 335, 1602-1603.	13.7	8
85	Production of polyclonal and monoclonal antibodies to human granulocyte colony-stimulating factor (GCSF) and development of immunoassays. Journal of Immunological Methods, 1990, 128, 211-217.	1.4	7
86	DEMONSTRATION OF CYTOKINES IN BIOLOGICAL MEDICINES PRODUCED IN MAMMALIAN CELL LINES. Lancet, The, 1989, 334, 1011-1012.	13.7	5
87	In vivo administration of interleukin 2 stimulates mitosis in thymus and bone marrow. European Journal of Immunology, 1986, 16, 1171-1174.	2.9	8
88	Interleukin 2 stimulates T cell proliferation using a calcium flux. Immunology Letters, 1985, 10, 297-302.	2.5	23
89	Impact of Formulation Choices on the Freeze-Drying of an Interleukin-6 Reference Material. Frontiers in Molecular Biosciences, 0, 9, .	3.5	1